On November 15, 2024, Evergreen Therapeutics and JUXIAN Pharmaceutical, announced the establishment of a long-term strategic cooperation. This strategic partnership signifies a deep collaboration between the two parties in the field of drug development. With the expertise in artificial intelligence, pharmaceuticals, and clinical technology, Evergreen Therapeutics will provide comprehensive support for JUXIAN Pharmaceutical's new drug development. This collaboration will not only accelerate the development process of new drugs but also promote continuous innovation in the field of innovative drugs. The collaboration between the two parties will further enhance the enhance the precision of drug development, improve the efficiency and success rate of drug development, and bring more high-

The fourth “Asia Summit on Global Health,” hosted by the Hong Kong Trade Development Council, was recently concluded with resounding success. A highlight of the event was Dr. Tom Du’s expert analysis of Hong Kong's future biomedical industry. As the Chairman of Evergreen Therapeutics and a former senior FDA reviewer, Dr. Tom Du, offered valuable perspectives during the summit’s expert roundtable session. This forum garnered significant attention from the Special Administrative Region Government, with notable leaders in attendance, including Chief Executive of the Hong Kong Special Administrative Region John Lee, Deputy Director of the National Health Commission Cao Xuegang, Chairman of the Hong Kong Trade Development Council Lin Zhenyu, and Director of the Department of Health of

Recently, the 5th Asian Cell and Gene Therapy Innovation Summit of CGT Asia 2024 and the 2nd 3D Cell Culture and Organoid R&D Summit of 3DCC were held in Shanghai. This event serves as the premier CGT industry conference in the Asia Pacific region, organized by Taas labs with support from the Shanghai Biomedical Industry Promotion Center and the Skin and Soft Tissue Repair and Reconstruction Technology Branch of the China Medical Biotechnology Association (TCMRR). Simultaneously, at this conference, the "CGT Awards" - a ceremony honoring outstanding achievements in the Asia Pacific Cell and Gene Therapy industry - was also conducted. The "CGT Awards Asia Pacific Cell and Gene Therapy Industry Star" award is an industry segmentation track selection initiated by Taas labs, aiming to pro

June 5, 2023, BojiMed Pharmaceutical Technology Co., Ltd. (stock code: 300404, hereinafter referred to as "BOJIMED"), a well-established domestic CRO listed company, and Shenzhen Evergreen Therapeutics Co. , Ltd. (hereinafter referred to as "Evergreen") Signing a strategic cooperation agreement , the two parties adhere to the principle of "complementary advantages, mutual benefit and win-win", use artificial intelligence (AI) to carry out strategic cooperation in the field of clinical trials, and jointly promote the efficient clinical development and commercialization of innovative drugs in multiple disease fields. By complementing each other's strengths and leveraging the advantages of their respective expert teams, AI can be used to solve bottleneck issues that affect drug research a

On February 17, the 2022 “Digital Health Companies China 50” list was released at the “2023 MIT Technology Review China Future Health” Summit. As one of the most important benchmarks of digital health, the list consists of 50 outstanding healthcare science and technology companies from six major fields that affect digital health. Among the 50, five promising AI-driven biotech companies including Evergreen Therapeutics, Insilico Medicine, XtalPi were recognized by virtue of their outstanding achievements in the field of digitalization of pharmaceutical R&D.Professor Mohamad Sawan (Fellow of the Canadian Academy of Engineering) address the forum As a US-China based AI-driven biopharmaceutical company, Evergreen Therapeutics is pioneering and highly differentiated in AI drug R&D. Th

On January 5, the "cloud-intelligence Integration, In-depth Life Science" activity of life science area "Intelligent Travel" was successfully held in Shenzhen by Baidu AI Cloud. Nearly 100 representatives from scientific research institutes, gene technology, well-known biopharmaceutical enterprises and Internet enterprises attended the meeting. Shenzhen Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") As a leader in the field of AI drug research and development in China, was invited to attend this event and serve as the keynote speaker.                                                Dr. Tao Hu, Director of Pharmaco

On September 15, the "Ernst & Young Fudan Most Potential Enterprise Award Ceremony 2022 and High Growth Enterprise Theme Seminar" hosted by Ernst & Young, the world's leading professional service organization, and the School of Management of Fudan University, a top university in China, kicked off in Shanghai. The "EY Fudan Most Potential Enterprise" list, which has attracted much attention from the industry, was officially announced. After authoritative, professional, and strict screening, Evergreen Therapeutics finally relying on the core founding and management team composed of years of experience in new drug research and development, FDA reviewers, and the industry's top clinical research and development and AI/quantum technology teams, R&D and business models, as well as high-s

On May 28, 2022, Dr. Tom Du, Chairman of Evergreen Therapeutics and Dr. Charles Lee, CMO of Evergreen Therapeutics attended the "First Academic Forum of HwaGen medical thinks markets 2022" sponsored by HwaGen Pharma. The conference was strongly supported by local governments, industry associations and research institutions.Dr. Tom Du making speech Dr. Charles Lee making speech At the meeting, a number of senior experts from the industry witnessed the launch ceremony of the one-stop CRO/CDMO platform of HwaGen Pharma, and discussed the future of small molecule innovative drugs. A roundtable discussion was held on the important role of small molecule new drugs in the fight against COVID-19 and how to better attract financing for innovative drug companies under the current situation

On September 13th, the four-day BIOHK2023 Hong Kong International Biotechnology Forum kicked off at the Hong Kong Convention and Exhibition Center, Supported by the China Association for Science and Technology, the Ministry of Science and Technology, and the Hong Kong Special Administrative Region Government. BIOHK2023 stands as a preeminent international biotechnology event initiated by the esteemed Hong Kong Biotechnology Association, boasting its status as one of Asia's largest conferences in this field. This gathering convenes numerous distinguished experts and academicians across diverse disciplines, including Nobel laureate Dr. Bruce Beutler, Academician Gao Fu from Chinese Academy of Sciences, Academician Han Jisheng, Dr. Wang Yu from former National Center for Disease Control a

Recently, the FDA Expert Association and Tigermed successfully held a salon with the theme of "Through the Cycle and Watch for Innovation" in Shanghai. Some members of the FDA Expert Association and the expert team from Tigermed gathered together to analyze the challenges faced by the pharmaceutical industry under the current international situation, and conducted in-depth discussions on how to apply new technologies such as artificial intelligence to empower clinical research.  At the salon event, Dr. He Ruyi, honorary president of the FDA Expert Association and chief scientist of SDIC Innovation, delivered a welcome speech and delivered a keynote speech titled "New Thinking on Clinical Trial Design." Led by Chairman He, the experts expressed their opinions and jointly provided sugge